Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Asensus Surgical Inc TRXCD


Primary Symbol: ASXC

Asensus Surgical, Inc. is a medical device company digitizing the interface between the surgeon and patient to reimagine surgery through Performance-Guided Surgery to enable surgeons to deliver outcomes to patients and establish a new standard of surgery. It operates in one business segment, which is the research, development and sale of medical device robotics to improve minimally invasive surgery. It is developing the LUNA Surgical System, a robotic and instrument system as a foundation of its Digital Surgery solution. These systems shall be powered by the Intelligent Surgical Unit to enhance surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, it intends to holistically address the clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. It is also working to incorporate all of this in the LUNA Surgical System.


NYSEAM:ASXC - Post by User

Post by tamarion Jan 13, 2023 11:28am
200 Views
Post# 35221200

Closing in on 10,000+ proecedures.

Closing in on 10,000+ proecedures.
That's critical mass of machine learning and opens up a lot of opportunities.  The commercial launch of articulating instruments in Q4 2022 was a long sought after key surgeon preference item.  That must be contributing to recent system placements in Germany and Japan.  Expect further traction now that we're moving on from Covid.

Today's breakout of the compressed moving averages is very positive.  Haven't seen that for 2 years. 
<< Previous
Bullboard Posts
Next >>